Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models.

Kim J-A, Seong R-K, Kumar M, Shin OS.

Citation

Kim J-A, Seong R-K, Kumar M, Shin OS. (2018) Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models. Viruses 10:72.

Abstract

Zika virus (ZIKV) has recently emerged as a new public health threat. ZIKV infections
have caused a wide spectrum of neurological diseases, such as Guillain-Barre syndrome, myelitis,
meningoencephalitis, and congenital microcephaly. No effective therapies currently exist for treating patients infected with ZIKV. Herein, we evaluated the anti-viral activity of favipiravir (T-705) and ribavirin against Asian and African strains of ZIKV using different cell models, including human neuronal progenitor cells (hNPCs), human dermal fibroblasts (HDFs), human lung adenocarcinoma cells (A549) and Vero cells. Cells were treated with favipiravir or ribavirin and effects on ZIKV replication were determined using quantitative real-time PCR and plaque assay. Our results demonstrate that favipiravir or ribavirin treatment significantly inhibited ZIKV replication in a dose-dependent manner. Moreover, favipiravir treatment of ZIKV-infected hNPCs led to reduced
cell death, enhanced AKT pathway phosphorylation, and increased expression of anti-apoptotic factor
B cell lymphoma. In conclusion, our results demonstrate conclusively that favipiravir inhibits ZIKV replication and prevents cell death, and can be a promising intervention for ZIKV-associated disease.